Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The U.K.-based drugmaker became the second to strike a deal with the Trump administration as part of the president's push to rein in U.S. drug prices. -
The Trump administration says it is making deals with drug companies to lower prices U.S. consumers pay for medicines. But key details are missing on how the initiative would work. -
A law firm appealing a stalled case against Tylenol's maker, Kenvue, says people are calling to join the suit, alleging the painkiller caused autism in children whose mothers took it during pregnancy. -
It's been a confusing and fast-changing couple of months for rules about getting a COVID shot. It should be a little easier now, after a panel of vaccine advisers met last week. -
Though the FDA narrowed criteria for the shots, many people still want them, to avoid illness and protect vulnerable family members. Some are turned down at the pharmacy or have to jump through hoops. -
Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet. -
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries. -
The action is intended to build upon the existing program for Medicare drug price negotiations, which was created by the Inflation Reduction Act that passed during the Biden administration. -
Staffers began receiving termination notices this morning as part of a major restructuring at HHS. Some senior leadership are on their way out too. -
With no help from the federal government, states are trying to regulate recreational marijuana. California's Department of Cannabis Control works to keep contaminants out of joints, vapes and edibles.
